Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Sarcoma 6Osteosarcoma 4Lymphoma 3Neoplasm Metastasis 2Melanoma 2Gliosarcoma 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Dendritic Cell Sarcoma, Interdigitating 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroblastoma 1Leukemia 1Histiocytic Sarcoma 1Glioma 1Eyelid Squamous Cell Carcinoma 1Endometrial Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Dendritic Cell Sarcoma, Follicular 1Chondrosarcoma 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Dendritic Cell Sarcoma, Follicular × Sarcoma × Clear all
NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Dana-Farber Cancer Institute

Phase 2 Suspended
18 enrolled 16 charts
LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡